TABIRAFUSP ALFA
UNII Y9CNJ2XD89

Substance Identification & Data

This profile provides standardized clinical and technical data for Tabirafusp Alfa, uniquely identified by the FDA Unique Ingredient Identifier (UNII) Y9CNJ2XD89.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2839527-15-8 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

Y9CNJ2XD89

CAS Registry Number

2839527-15-8

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

TABIRAFUSP ALFA

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C211827

National Cancer Institute reference terminology for clinical and research data.

INN ID

13243

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

NO-194

Identifier assigned by the United States Adopted Names Council.

Substance Type

Tabirafusp Alfa

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Tabirafusp Alfa. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Tabirafusp Alfa

Common Names & Synonyms

Human vascular endothelial growth factor receptor 1 (VEGFR-1) fragment containing immunoglobulin-like extracellular domain 2 (103-206, 1-104 in the current sequence) fused to a human vascular endothelial growth factor receptor 2 (VEGFR-2) fragment containing immunoglobulin-like extracellular domain 3 (208-308, 105-205 in the current sequence) fused via peptide linker GGGGSGGGGS (206-215) to the gamma 1 heavy chain of anti-[human interleukin 6 (IL-6)] (216-664) [VH (Homo sapiens IGHV3-23*03 -(IGHD) -IGHJ3*02, CDR-Kabat [5.17.10] (246-250.265-281.314-323)) (216-334) -Homo sapiens IGHG1*03 R431>K (CH1 (335-432), hinge (433-447), CH2 L451>A, L452>A, G454>A (448-557), CH3 L660>C (558-662), CHS (663-664)) (335-664)], (437-213')-disulfide with kappa light chain anti-[human interleukin 6 (IL-6)] (1'-213') [V-KAPPA (Homo sapiens IGKV1-13*02 -IGKJ1*01, CDR-Kabat [10.7.9] (24'-33'.49'-55'.88'-96')) (1'-106') -Homo sapiens IGKC*01 (107'-213')]; dimer (443-443'':446-446'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1SV, glycoform alfa

KSI-101 component OG2072 antibody

TABIRAFUSP ALFA [USAN]

Vascular endothelial growth factor receptor 1 (human extracellular immunoglobulin domain 2 fragment) fusion protein with vascular endothelial growth factor receptor 2 (human extracellular immunoglobulin domain 3 fragment) fusion protein with peptide linker ((GGGGS)2) fusion protein with immunoglobulin G1 [236-alanine,237-alanine,239-alanine,445-cysteine] anti-(human interleukin 6) (human monoclonal OG2072 γ1-chain), disulfide with human monoclonal OG2072 κ-chain, dimer

tabirafusp alfa [INN]